What sector does Amgen belong to?

Amgen operates in the Health Care sector, specifically the Biotechnology industry, and is listed on the US markets.

What is the current share price of AMGN?

As of the latest available quote, AMGN traded at $377.35. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of AMGN?

Amgen has a price-to-earnings (P/E) ratio of about 23.42. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of AMGN?

The market capitalisation of Amgen is approximately $204.48B.

For its latest reported financial year, Amgen recorded a net profit margin of about 20.98%.

Does AMGN pay a dividend?

Amgen currently has a dividend yield of about 2.56%.

What is the return on equity (ROE) of AMGN?

Amgen has a return on equity (ROE) of about 65.97%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of AMGN?

Over the past 52 weeks, AMGN has traded between a low of $269.77 and a high of $447.03.

Amgen

AMGN US Health Care Biotechnology

S&P 500 Nasdaq 100 Dow Jones

$377.35

-1.34%

Delayed · cached 15 min

Fair value analysis

AMGN

Amgen

$377.35

Close used for this calculation

$271.17Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

49/100

Profitability19/25

Returns12/25

Balance Sheet7/25

Efficiency11/25

Growth6/25

Average

Quality radar

Consensus fair value

$271.17

Above FV

▼ -28.1% against the close used

Model range $82.95 – $355.50

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$82.95Fair value$271.17Bull$355.50

FairClose

52-week traded range

52W low $271.1852W high $444.12

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Amgen closed at $377.35, 39.2% above the consensus fair value of $271.17 drawn from 8 valuation models.

Financial DNA score 49/100 — Average. P/E of 26.5x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$265.89

-29.5%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=7.1%, r=10%, tg=3%, n=10yr

Graham Number

$82.95

-78.0%

√(22.5 × EPS × BVPS)

EPS=14.23, BVPS=21.49 · outside Graham range (P/E 26.5, P/B 17.6) — asset-light, treat as a rough floor

P/E Fair Value

$284.60

-24.6%

EPS × 20x (sector P/E)

EPS=14.23, Sector P/E=20x

Peter Lynch (PEG)

$100.89

-73.3%

EPS × Growth% (PEG = 1 is fair)

EPS=14.23, g=7.1%

EV/EBITDA

$272.20

-27.9%

(EBITDA × 13.5x − Net Debt) ÷ Shares

EBITDA=14.25B

Dividend Discount (DDM)

$355.50

-5.8%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=9.66, r=10%, g=7.1%

Reverse DCF

$377.35

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 10.9% | Historical: 7.1%

Margin of Safety

$158.36

-58.0%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=211.15, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer